LEVULAN Drug Patent Profile

When do Levulan patents expire, and what generic alternatives are available?

Levulan is a drug marketed by Sun Pharm Inds Inc and is included in one NDA. There are ten patents protecting this drug.

This drug has twenty-eight patent family members in seven countries.

The generic ingredient in LEVULAN is aminolevulinic acid hydrochloride. There are six drug master file entries for this compound. Four suppliers are listed for this compound. Additional details are available on the aminolevulinic acid hydrochloride profile page.

DrugPatentWatch^® Generic Entry Outlook for Levulan

Levulan was eligible for patent challenges on December 3, 2003.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be October 13, 2036. This may change due to patent challenges or generic licensing.

There have been five patent litigation cases involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.

Indicators of Generic Entry

Summary for LEVULAN

International Patents:	28
US Patents:	10
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	117
Clinical Trials:	32
Patent Applications:	563
Drug Prices:	Drug price information for LEVULAN
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for LEVULAN
DailyMed Link:	LEVULAN at DailyMed

See drug prices for LEVULAN

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for LEVULAN

Constraining patent/regulatory exclusivity:

12,290,700

NDA:

020965

Dosage:

SOLUTION;TOPICAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for LEVULAN

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Sun Pharmaceutical Industries, Inc.	PHASE3
Nathalie Zeitouni	PHASE1
National Institutes of Health (NIH)	Phase 2

See all LEVULAN clinical trials

US Patents and Regulatory Information for LEVULAN

LEVULAN is protected by ten US patents.

This potential generic entry date is based on patent 12,290,700.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Sun Pharm Inds Inc	LEVULAN	aminolevulinic acid hydrochloride	SOLUTION;TOPICAL	020965-001	Dec 3, 1999		RX	Yes	Yes	11,690,914
Sun Pharm Inds Inc	LEVULAN	aminolevulinic acid hydrochloride	SOLUTION;TOPICAL	020965-001	Dec 3, 1999		RX	Yes	Yes	12,296,011
Sun Pharm Inds Inc	LEVULAN	aminolevulinic acid hydrochloride	SOLUTION;TOPICAL	020965-001	Dec 3, 1999		RX	Yes	Yes	11,697,028
Sun Pharm Inds Inc	LEVULAN	aminolevulinic acid hydrochloride	SOLUTION;TOPICAL	020965-001	Dec 3, 1999		RX	Yes	Yes	10,357,567
Sun Pharm Inds Inc	LEVULAN	aminolevulinic acid hydrochloride	SOLUTION;TOPICAL	020965-001	Dec 3, 1999		RX	Yes	Yes	11,077,192
Sun Pharm Inds Inc	LEVULAN	aminolevulinic acid hydrochloride	SOLUTION;TOPICAL	020965-001	Dec 3, 1999		RX	Yes	Yes	12,290,700
Sun Pharm Inds Inc	LEVULAN	aminolevulinic acid hydrochloride	SOLUTION;TOPICAL	020965-001	Dec 3, 1999		RX	Yes	Yes	11,179,574

Expired US Patents for LEVULAN

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Sun Pharm Inds Inc	LEVULAN	aminolevulinic acid hydrochloride	SOLUTION;TOPICAL	020965-001	Dec 3, 1999	5,954,703
Sun Pharm Inds Inc	LEVULAN	aminolevulinic acid hydrochloride	SOLUTION;TOPICAL	020965-001	Dec 3, 1999	6,710,066
Sun Pharm Inds Inc	LEVULAN	aminolevulinic acid hydrochloride	SOLUTION;TOPICAL	020965-001	Dec 3, 1999	5,079,262
Sun Pharm Inds Inc	LEVULAN	aminolevulinic acid hydrochloride	SOLUTION;TOPICAL	020965-001	Dec 3, 1999	5,422,093
Sun Pharm Inds Inc	LEVULAN	aminolevulinic acid hydrochloride	SOLUTION;TOPICAL	020965-001	Dec 3, 1999	7,723,910
Sun Pharm Inds Inc	LEVULAN	aminolevulinic acid hydrochloride	SOLUTION;TOPICAL	020965-001	Dec 3, 1999	6,709,446
Sun Pharm Inds Inc	LEVULAN	aminolevulinic acid hydrochloride	SOLUTION;TOPICAL	020965-001	Dec 3, 1999	5,211,938

International Patents for LEVULAN

When does loss-of-exclusivity occur for LEVULAN?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Australia

Canada

European Patent Office

Japan

Poland

Spain

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering LEVULAN around the world.

Country	Patent Number	Title	Estimated Expiration
Australia	2019200152	Methods for photodynamic therapy
Australia	2020103365	Methods for photodynamic therapy
Australia	2020267186	Methods for photodynamic therapy
Australia	2021102111	Methods for photodynamic therapy
Australia	2021107564	Methods for photodynamic therapy
Australia	2022209242	METHODS FOR PHOTODYNAMIC THERAPY
Australia	2024205278	METHODS FOR PHOTODYNAMIC THERAPY

Last updated: June 15, 2026

rket Dynamics and Financial Trajectory for LEVULAN (aminolevulinic acid HCl) LEVULAN (aminolevulinic acid HCl) is a prescription photodynamic therapy product used for superficial basal cell carcinoma (sBCC) and actinic keratosis (AK) with FDA-approved indications based on light activation. Public financial disclosures are limited because LEVULAN is typically reported as part of broader company segments and because revenues can be aggregated across dermatology and specialty product lines. As a result, available market dynamics must be read through channel structure (specialty derm and procedural mix), utilization drivers (lesion burden and payer coverage), and competitive replacement risk from other PDT and non-PDT dermatologic options.

How big is the LEVULAN market and what drives demand in sBCC and actinic keratosis?

Answer: Demand is driven by dermatologist and procedural clinic adoption for lesion-directed care, payer acceptance for sBCC and AK pathways, and scheduling/uptake of photodynamic therapy workflows. Growth is constrained by (1) the seasonal and adherence variability of AK treatment, (2) geographic reimbursement differences for PDT, and (3) substitution by lesion-directed regimens that avoid the procedural light-activation step.

What utilization factors matter most for LEVULAN?

Key demand levers in dermatology PDT products:

• Clinician workflow fit: PDT requires time for curette/dermprep, daylight or red-light activation, and patient instructions. Uptake increases when clinics standardize protocols.
• Patient selection: Market penetration follows where guidelines and payer policies support PDT for AK and sBCC alternatives.
• Reimbursement and coverage policy: Coverage often determines whether AK is treated with field therapy (topicals) vs lesion-directed procedural care.
• Endpoint economics: The ability to demonstrate clearance rates and durability influences payer and formulary retention.

How do the sBCC vs AK indications affect revenue mix?

• sBCC is more episodic and procedure-driven. Uptake depends on how often dermatologists see eligible sBCC and how frequently patients choose PDT relative to excision, Mohs, or topical regimens.
• AK has higher patient-volume potential but often shifts with payer formularies toward field-directed topicals, cryotherapy, and newer lesion-directed modalities. PDT remains relevant where clinicians seek cosmetic outcomes and where payers reimburse adequately.

Who competes with LEVULAN in photodynamic therapy and dermatology lesion care?

Answer: LEVULAN competes against other photodynamic therapy offerings and lesion-directed dermatologic treatments across AK and sBCC treatment algorithms. Competitive pressure is primarily substitution for eligible patients, not direct class-to-class “switching” in every case.

Which alternative PDT and non-PDT options pressure LEVULAN uptake?

Competitor categories affecting LEVULAN:

• Other PDT products (different photosensitizers and formulations): Compete on light-activation convenience, patient tolerance, and reimbursement.
• Topical field therapies for AK: Compete by simplifying visits and reducing procedural steps.
• Lesion-directed procedures: Cryotherapy and surgical options compete through speed, payer familiarity, and clinician routine.
• Emerging dermatology modalities: New lesion-directed treatments can displace PDT when they meet coverage and ease-of-use expectations.

How does competitive switching typically happen?

• Clinical preference: Providers choose PDT when they value cosmetic outcome and lesion response.
• Payer policy: Prior authorization or step therapy can slow adoption and reduce repeat utilization.
• Operational capacity: PDT requires lighting setup and scheduling discipline. Clinics with tight throughput can favor faster procedures.

What is the pricing and reimbursement structure for LEVULAN, and how can it impact financial trajectory?

Answer: Pricing and reimbursement outcomes govern net sales durability. PDT products face scrutiny under specialty pharmacy and buy-and-bill models, with payer coverage variability changing the effective price and utilization.

How reimbursement can move LEVULAN revenue

• Formulary access: Favorable coverage increases eligible patient volume.
• Site of care: Clinic buy-and-bill economics can differ from pharmacy-dispensed models, affecting physician incentives and patient out-of-pocket costs.
• Coding and administration: Reimbursement sensitivity to treatment visits and administration codes can shift net revenue even if list price remains stable.
• Prior authorization: Slower approvals reduce conversion of eligible patients.

What is LEVULAN’s financial trajectory by timeline: launch, growth, maturity, and plateau?

Answer: LEVULAN’s financial trajectory is consistent with a specialty dermatology product that matures under stable clinical adoption, then faces periodic growth headwinds from formulary dynamics, competitive substitution, and any changes to label scope, administration protocols, or payer utilization.

Mapped phases for a mature dermatology PDT brand

Because LEVULAN’s revenues are not consistently broken out in widely accessible public datasets at product-level granularity, the observable trajectory typically follows:

• Early growth: Provider adoption, initial payer uptake, and expansion from pilot clinic networks.
• Maturity: Stable prescribing under established workflows and repeat usage for recurrence/maintenance cycles where clinically supported.
• Plateau risk: Loss of exclusivity risk is often paired with competitive products, though PDT ecosystems can keep some brands resilient when workflows remain entrenched.
• Renewed pressure points: Updates in payer policy, higher competitive intensity, or shifts toward non-PDT regimens reduce growth.

Does LEVULAN face generic or biosimilar substitution risk, and what changes the revenue outlook?

Answer: Substitution risk depends on patent and market exclusivity status for the specific photosensitizer, formulation, and FDA-approved labeling. For LEVULAN, revenue outlook hinges on whether credible generic alternatives can enter with acceptable bioequivalence, labeling parity, and payer acceptance.

What controls generic entry likelihood for PDT drugs?

• Active ingredient salt and formulation constraints: Generic substitution depends on formulation-specific approval and labeling alignment.
• Label and indication coverage: Even when generics launch, payer coverage can remain less favorable if indications are narrower or if clinicians perceive differences.
• Access and stocking behavior: Clinics may resist switching until compelled by pricing or supply constraints.

How strong is the patent estate for LEVULAN, and what does it imply for long-term revenue?

Answer: Long-term exclusivity and patent barriers determine the durability of pricing power and reduce the probability of abrupt net sales compression from generic entry. Without a validated, product-specific patent table tied to LEVULAN’s exact label, claims, and jurisdictions, a precise expiration-by-expiration view cannot be produced.

What FDA and Orange Book status affects LEVULAN market exclusivity?

Answer: LEVULAN’s market exclusivity posture is determined by its FDA approval history, listed patents in the Orange Book, and any unexpired exclusivity periods attached to the NDA/BLA. A complete status view requires the current Orange Book listing for the specific NDA and strength for each listed patent.

What litigation or Paragraph IV activity would be material to LEVULAN’s financial forecast?

Answer: Material financial inflection events usually come from generic patent challenges that drive settlement and launch timing. A precise view of Paragraph IV risk requires current docket-linked facts and patent-to-Orange-Book mapping for LEVULAN. Without that mapping, a correct litigation timeline cannot be compiled.

Commercial forecast drivers: utilization growth vs. price erosion

Answer: LEVULAN’s financial trajectory is the net result of two forces:

1. Utilization changes driven by dermatology incidence mix (AK burden), clinical protocol adoption, and payer coverage.
2. Price and channel changes driven by procurement contracts, reimbursement rates, and any competitive pressure from alternative PDT and non-PDT regimens.

How to interpret “growth” for mature PDT brands

• Growth in mature PDT often comes from share gains (more patients choosing PDT) rather than overall market expansion.
• Share gains are sensitive to formulary status and clinic adoption of standardized protocols.

Key risks to LEVULAN revenue and market share

Answer: The primary revenue risks are competitive substitution, reimbursement friction, and potential generic entry timing. The probability-weighted outcome depends on exclusivity status and the strength of listed intellectual property supporting the approved use.

Risk register (high-level)

• Competitive displacement: Alternative PDT systems, topicals, or procedures reduce eligible patient selection.
• Reimbursement setbacks: Prior authorization tightening, lower effective reimbursement, or site-of-care changes.
• Operational friction: Clinic workload constraints limit consistent PDT delivery.
• Regulatory and labeling changes: Any narrowing of indications or shifts in administration requirements affect addressable use.
• Exclusivity erosion: Generic entry can compress net price and reduce volumes if reimbursement supports substitution.

What does LEVULAN’s competitive landscape mean for investors and licensors?

Answer: For investors and licensing counterparties, the relevant question is not total dermatology spend, but the persistence of PDT share within AK/sBCC lines of care. Under mature conditions, returns are driven by exclusivity duration, pricing stability, and the degree to which clinicians and payers keep PDT in the treatment algorithm.

Licensing and co-promotion considerations

• Licensing value increases when exclusivity is intact and when clinical adoption is stable enough to support predictable utilization.
• If exclusivity is close to expiry or patent challenges are active, transaction terms tend to incorporate launch-risk discounting and milestone-based protections.

Key Takeaways

• LEVULAN demand is driven by dermatology procedural workflow adoption and payer coverage within AK and sBCC care pathways.
• Financial trajectory typically follows a mature specialty pattern: stable utilization tempered by price and formulary dynamics and competitive substitution.
• The highest-impact inflection risks are reimbursement shifts and exclusivity erosion that can enable lower-priced alternatives.
• A precise exclusivity, patent-expiration, litigation, and Orange Book status impact assessment requires product-specific NDA-level mapping to current FDA listings and dockets.

FAQs

1. How do payer policies for actinic keratosis affect LEVULAN net sales realization?
2. Which treatment choices most commonly substitute for LEVULAN in superficial basal cell carcinoma?
3. What operational factors in dermatology clinics limit photodynamic therapy throughput and constrain LEVULAN volumes?
4. How would a generic launch of a LEVULAN-equivalent PDT product typically change prescription behavior?
5. What Orange Book-listed patents or exclusivity terms are most likely to determine LEVULAN’s end-of-exclusivity date?

References

1. FDA Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations (search database). https://www.accessdata.fda.gov/scripts/cder/daf/
2. U.S. FDA Drug Approval Reports and Labels (Drugs@FDA). https://www.accessdata.fda.gov/scripts/cder/daf/
3. FDA Drug Approval Package for LEVULAN (aminolevulinic acid HCl), label and prescribing information (Drugs@FDA). https://www.accessdata.fda.gov/scripts/cder/daf/

DrugChatter Q&A for LEVULAN

How does levulan kerastick work with light therapy?